Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Pulmonary Tuberculosis Participants between 18 to 60 years of age inclusive at the time of signing the informed consent Body weight within 40 and 100 kilogram (inclusive) Untreated, rifampicin-sensitive pulmonary tuberculosis, as defined by all of the following: 1. isoniazid urine screen negativity 2. sputum smear positivity on direct microscopy for acid-fast bacilli, defined as at least 1+ on the International Unit Against Tuberculosis and Lung Disease/ World Health Organization scale 3. chest X-rays which in the opinion of the investigator is consistent with tuberculosis (TB). 4. Mycobacterium tuberculosis (Mtb) positivity on molecular test (GeneXpert®) 5. rifampicin sensitivity on molecular test (GeneXpert®) Participants must be able to produce at least 10 milliliter of sputum during the overnight sputum collection (day -7 to -3 or day -2 of the Screening Phase) Female and male participants should be of non-childbearing potential or using an effective method of birth control Non-childbearing potential is defined as follows: 1. participant is not heterosexually active or practices sexual abstinence, OR 2. female participant or sexual partner has undergone bilateral oophorectomy, bilateral tubal ligation and/or hysterectomy, OR 3. female participant or sexual partner has been postmenopausal with a history of no menses for at least 12 consecutive months, OR 4. male participant or sexual partner has undergone vasectomy or bilateral orchidectomy at least three months prior to screening, OR 5. male participant with pregnant sexual partner (for duration of the study) who does not have any other sexual partners An effective method of birth control is defined as follows: 1. double barrier method, which can any 2 of the following: a male condom, diaphragm, cervical cap, or female condom (male and female condoms should not be used together), OR 2. barrier method (one of the above) combined with hormone-based contraceptives or an intra-uterine device for the female participant or partner, AND 3. participant willing to continue practicing one of the above-mentioned birth control methods throughout 14-day Study Treatment Phase and for 4 weeks after the last dose of study medication or discontinuation from study medication in case of early withdrawal Participants must be capable of giving signed informed consent, which includes agreeing to compliance with the requirements and restrictions listed in the informed consent form and the protocol  Need for immediate effective anti-TB treatment as judged by the investigator Evidence and/or history of extra-thoracic TB (e.g. miliary TB, abdominal TB, urogenital TB, osteoarthritic TB, TB meningitis, ocular TB), as judged by the investigator Evidence and/or history in the last 5 years of one or any combination of the following: 1. uveitis; 2. color vision deficiency; 3. amblyopia; 4. visual acuity worse than 20/25 after correction in either eye; 5. any known eye disease or prior eye surgery; 6. any systemic condition with ocular manifestations (i.e. Marfan, syphilis, diabetes, Beçhet, Vogt-Koyanagi-Harada, Lyme, or chronic inflammatory condition such as sarcoidosis, rheumatoid arthritis, psoriatic arthritis) Evidence and/or history in the last 5 years of clinically significant medical condition(s) as judged by the investigator, including malignancies and unstable or uncontrolled hypertension Any current medical, psychiatric, occupational, or substance abuse problems that, in the opinion of the investigator, will make it unlikely that the participant will comply with the protocol For Human Immunodeficiency Virus infected participants: 1. CD4+ count <350 cells/microliter, OR 2. Acquired Immune Deficiency Syndrome-defining opportunistic infection or malignancies (except pulmonary TB) Seated systolic/diastolic blood pressure assessed as vital sign [i.e. not from electrocardiogram (ECG)] is less than 95/40 millimeters of Mercury (mmHg) or greater than 145/95 mmHg at screening. Out-of-range blood pressure may be repeated twice with at least 5 minutes intervening Seated heart rate assessed as vital sign (i.e. not from ECG) is lower than 40 beats per minute (bpm) or higher than 110 bpm at screening. Out-of-range heart rate may be repeated twice with at least 5 minutes intervening A clinically significant ECG abnormality at screening. NOTE: The following can be considered not clinically significant: 1. mild first-degree atrio-ventricular block (P-R interval <0.23 seconds); 2. right or left axis deviation; 3. incomplete right bundle branch block; 4. isolated left anterior fascicular block (left anterior hemiblock) in young athletic participants A list of commonly used prohibited medications with the features described below are prohibited